Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cimen, Akcay"'
Publikováno v:
Journal of Cancer Research and Therapeutics. 16:752
In extensive-disease-small cell lung cancer (ED-SCLC), the median survival is 8-10 months and 2-year survival is5%. Primary tumor progression occurs in 90% of patients approximately within 1 year. The role of consolidative thoracic radiotherapy (C-TR
Autor:
Ufuk Yilmaz, Ülkü Yılmaz, Esra Korkmaz Kirakli, Cimen Akcay, Serhat Erol, Nilgün Yılmaz Demirci, Zehra Yasar, Burcu Öztürk Şahin, Deniz Koksal, Yasemin Özdoğan, Ilker Ozdogan, Sukran Ulger
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 12, Iss 1, Pp 334-339 (2016)
WOS:000378176100060 PubMed: 27072260 Aim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent
Autor:
Kemal, Ekici, Tumay, Gokce, Ilker, Karadogan, Aysun, Fatma Eraslan, Cimen, Akcay, Oztun, Temelli, Eda, Kaya Pepele, Funda, Durmus Manalp, Caglar, Keles, Arpaslan, Mayadagli
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 21(1)
This study describes the early clinical results and dosimetric parameters of intensity-modulated radiation therapy (IMRT) using a tomotherapy device in patients with primary bilateral synchronous breast cancer (PSBBC).Fourteen patients with bilateral
Publikováno v:
Journal of Thoracic Oncology. 2(8)
Autor:
Gulden, Diniz, Ismet, Unlu, Tumay, Gokce, Sevil, Kilciksiz, Mine, Gayaf, Berna, Komurcuoglu, Ilker, Karadogan, Safiye, Aktas, Cimen, Akcay
Publikováno v:
Saudi medical journal. 27(7)
To evaluate the efficacy of curative and palliative radiotherapy in the treatment of extensive stage small cell lung cancer (E-SCLC), and compare therapy effect on survival with or without metastatic disease.From January 1998 through December 2004, 1
Autor:
Ismet, Unlu, Gulden, Diniz, Berna, Komurcuoglu, Mine, Gayaf, Tumay, Gokce, Ilker, Karadogan, Cimen, Akcay
Publikováno v:
Saudi medical journal. 27(6)
To evaluate the efficacy of curative and palliative radiotherapy in inoperable advanced non-small cell lung cancer (NSCLC) patients with a performance status (PS) equal or greater than 2, and to compare the therapy effect on survival with or without